We are live on !
Find out more
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter Est. Return
+18.5%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$31.2M
(+1.6%)
Cap. Flow
+$169M
Cap. Flow % of AUM
Cap. Flow %
8.75%
Top 10 Holdings %
Top 10 Hldgs %
45.68%
Holding
151
New
31
Increased
40
Reduced
42
Closed
31
Avg Time Held
Equity + Options
1
year
Top 10 Avg Time Held
Equity + Options
0.8
years
Top 20 Avg Time Held
Equity + Options
1.2
years
Avg Time Held Equity only
1
year
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
1.1
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
The Ensign Group
ENSG
|
+$104M |
| 2 |
Encompass Health
EHC
|
+$86.2M |
| 3 |
CareTrust REIT
CTRE
|
+$42.1M |
| 4 |
UnitedHealth
UNH
|
+$19M |
| 5 |
Insmed
INSM
|
+$18.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
GSK
GSK
|
+$68.9M |
| 2 |
Natera
NTRA
|
+$44.5M |
| 3 |
Healthpeak Properties
DOC
|
+$32.5M |
| 4 |
Avantor
AVTR
|
+$23.3M |
| 5 |
Qiagen
QGEN
|
+$20.3M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 89.53% |
| 2 | Real Estate | 5.59% |
| 3 | Miscellaneous | 4.84% |
| 4 | Financials | 0.05% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
26
UnitedHealth
UNH
$375B
| $21.3M | 1.1% |
+51,145
| New | +$19M |
2026 Q2
0 quarters
|
|
27
Welltower
WELL
$171B
| $19.8M | 1.03% |
87,312
-93,641
| -52% | -$19.8M |
2026 Q1
1 quarter
|
|
28
Beta Bionics
BBNX
$1.03B
| $19.6M | 1.02% |
1,249,441
-165,397
| -12% | -$1.97M |
2025 Q4
2 quarters
|
|
29
Cogent Biosciences
COGT
$5.42B
| $19M | 0.98% |
+490,235
| New | +$17.2M |
2026 Q2
0 quarters
|
|
30
BioCryst Pharmaceuticals
BCRX
$1.95B
| $18.7M | 0.97% |
1,865,653
-1,174,167
| -39% | -$10.6M |
2022 Q4
14 quarters
|
|
31
Molina Healthcare
MOH
$10.9B
| $18.4M | 0.96% |
80,594
+47,783
| +146% | +$8.66M |
2025 Q1
5 quarters
|
|
32
Pennant Group
PNTG
$1.46B
| $17M | 0.88% |
460,272
+148,094
| +47% | +$4.84M |
2025 Q2
4 quarters
|
|
33
LTC Properties
LTC
$2.36B
| $16.2M | 0.84% |
420,640
+99,594
| +31% | +$3.78M |
2026 Q1
1 quarter
|
|
|
34
Insmed
INSM
$20.4B
| $15.9M | 0.83% |
+149,209
| New | +$18.1M |
2026 Q2
0 quarters
|
|
35
Viridian Therapeutics
VRDN
$2.53B
| $15.3M | 0.79% |
831,142
+117,873
| +17% | +$1.9M |
2023 Q3
11 quarters
|
|
36
BioMarin Pharmaceuticals
BMRN
$10.8B
| $14.3M | 0.74% |
249,607
+41,839
| +20% | +$2.29M |
2025 Q3
3 quarters
|
|
37
AMN Healthcare
AMN
$1.86B
| $13.9M | 0.72% |
+428,531
| New | +$11.1M |
2026 Q2
0 quarters
|
|
38
Celcuity
CELC
$3.19B
| $13.4M | 0.69% |
+127,931
| New | +$14.8M |
2026 Q2
0 quarters
|
|
39
Pharvaris
PHVS
$2.21B
| $13.4M | 0.69% |
386,383
-20,577
| -5% | -$623K |
2025 Q4
2 quarters
|
|
40
CytomX Therapeutics
CTMX
$506M
| $13.3M | 0.69% |
3,558,497
+369,983
| +12% | +$1.41M |
2025 Q4
2 quarters
|
|
41
Humana
HUM
$50.7B
| $12.4M | 0.64% |
+31,171
| New | +$8.87M |
2026 Q2
0 quarters
|
|
42
Xenon Pharmaceuticals
XENE
$3.42B
| $11.9M | 0.62% |
196,532
+66,958
| +52% | +$3.72M |
2025 Q4
2 quarters
|
|
43
Corvus Pharmaceuticals
CRVS
$886M
| $11.2M | 0.58% |
+747,994
| New | +$10.4M |
2026 Q2
0 quarters
|
|
44
Ascendis Pharma A/S
ASND
$16B
| $11.1M | 0.58% |
+41,621
| New | +$9.7M |
2026 Q2
0 quarters
|
|
45
Bruker
BRKR
$8.77B
| $11M | 0.57% |
182,894
+65,881
| +56% | +$3.07M |
2024 Q4
6 quarters
|
|
46
Moderna
MRNA
$79.9B
| $10.7M | 0.55% |
152,122
-7,586
| -5% | -$392K |
2025 Q4
2 quarters
|
|
47
Structure Therapeutics
GPCR
$1.51B
| $10.5M | 0.55% |
196,302
+58,266
| +42% | +$2.58M |
2025 Q2
4 quarters
|
|
|
48
CALL
Insmed
INSM
$20.4B
| $10.3M | 0.53% |
96,600
+2,600
| +3% | +$315K |
2026 Q1
1 quarter
|
|
49
Definium Therapeutics
DFTX
$4.79B
| $10.2M | 0.53% |
217,185
+56,462
| +35% | +$1.4M |
2026 Q1
1 quarter
|
|
50
Compass Pathways
CMPS
$1.55B
| $9.5M | 0.49% |
672,825
-5,099
| -0.8% | -$51.8K |
2026 Q1
1 quarter
|
|
Similar funds
Eversept Partners's Q2 2026 Portfolio in Review
As of Q2 2026, Eversept Partners held 151 positions worth $1.93B, up 1.6% from $1.9B the previous quarter. Its ten largest holdings account for 46% of the portfolio.
Eversept Partners deployed $169M of net new capital in Q2 2026, opening 31 new positions and adding to 40 existing holdings. Its largest new stake was CareTrust REIT: 1,072,015 shares worth $43.3M.
By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 74% a quarter earlier, followed by Real Estate and Miscellaneous.
On the sell side, the largest reduction was GSK, an estimated $68.9M trimmed.
- Eversept Partners's largest Q2 2026 buy was CareTrust REIT: 1,072,015 shares worth $43.3M.
- Eversept Partners added most to The Ensign Group in Q2 2026, an estimated $104M increase.
- Eversept Partners's biggest Q2 2026 reduction was GSK, cutting an estimated $68.9M.
- Eversept Partners fully exited Healthpeak Properties in Q2 2026, selling an estimated $32.5M.
- Eversept Partners's ten largest holdings make up 46% of its $1.93B portfolio in Q2 2026.
- Eversept Partners opened 31 new positions and closed 31 in Q2 2026.
- Eversept Partners's portfolio value rose 1.6% quarter-over-quarter to $1.93B.
Based on Eversept Partners's 13F filing for Q2 2026, filed 14 Aug 2026.